Furthermore, the combination of anti-CTLA-4 (Tremelimumab) and anti-PD-L1 (Durvalumab) may improve overall survival (OS) in patients with advanced recurrent CRC and may be more effective than targeting anti-CTLA-4 alone in CRC [78]. Here, CTLA4 is linked to colorectal carcinoma.